Voyager Therapeutics (VYGR) Other Non-Current Liabilities (2014 - 2024)

Voyager Therapeutics has disclosed Other Non-Current Liabilities across 11 years of filings, most recently posting $39.4 million for Q3 2024.

• Other Non-Current Liabilities for Q3 2024 came in at $39.4 million, up 108.09% year-over-year; the trailing twelve-month figure through Sep 2024 was $39.4 million (up 108.09% YoY), and the FY2023 annual result was $18.1 million, down 15.03% from the prior year.
• Other Non-Current Liabilities came in at $39.4 million for Q3 2024 at Voyager Therapeutics, down from $41.2 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $44.4 million in Q4 2020 to a low of $18.1 million in Q4 2023.
• The 5-year median for Other Non-Current Liabilities is $31.1 million (2020), against an average of $31.9 million.
• Across the five-year window, Other Non-Current Liabilities tumbled 46.3% in 2022 and surged 109.51% in 2024, its largest moves.
• Voyager Therapeutics' Other Non-Current Liabilities stood at $44.4 million in 2020, then decreased by 10.81% to $39.6 million in 2021, then plunged by 46.24% to $21.3 million in 2022, then slipped by 15.03% to $18.1 million in 2023, then surged by 117.57% to $39.4 million in 2024.
• The last three Other Non-Current Liabilities figures came in at $39.4 million (Q3 2024), $41.2 million (Q2 2024), and $43.0 million (Q1 2024), per Business Quant data.